Azopharma takes equity stake in biotech

By Nick Taylor

- Last updated on GMT

Related tags: Contract research organization, Pharmacology

In exchange for services Azopharma is set to take almost 100 per cent equity in ImmuneRegen Biosciences, a biotech with products that are approaching Phase I and being eyed by big pharma, according to its CEO.

Speaking to Outsourcing-Pharma Michael Wilhelm, CEO of ImmuneRegen, explained that his company is “very excited​” to work with Azopharma and has been impressed by the diligence of the contract research organisation (CRO).

Giving an example Wilhelm said that ImmuneRegen had anticipated it taking nine to 12 months to complete toxicology and pharmacokinetic (PK) work in preparation for Phase I but Azopharma has put in a six to nine month timeline.

Azopharma also moved quickly when offered the chance to acquire equity in ImmuneRegen, according to Wilhelm who explained that he had approached two other CROs but they were slower to act.

The CRO will now work to develop Homspera, ImmuneRegen’s lead candidate, providing manufacturing, formulation development and safety studies as it approaches its investigational new drug (IND) application.

Once a therapeutic enters the clinic it receives increased attention from potential partners, according to Wilhelm who added that ImmuneRegen has relationships with big pharmas that may be interested in the treatment.

Selection of Azopharma

Azopharma did some early work with ImmuneRegen but the catalyst for the latest deal was when the CRO contacted the biotech as part of its efforts to reach out to potential clients.

ImmuneRegen believes that the breadth of Azopharma’s development services and experience of inhaled drugs and medical devices make the CRO a suitable collaborator.

The biotech has also contracted Bachem to be the primary manufacturer of Homspera and is nearing completion of a capital raising effort.

Related news

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more